Prednisone/tocilizumabNeutropenia following off-label use and rebound effect in the form of recurrence of scleritis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1817卷 / 1期

关键词：

D O I：

10.1007/s40278-020-82241-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：282 / 282

相关论文

共 50 条

[1] TocilizumabNeutropenia following off-label use: case report
Reactions Weekly, 2021, 1853 (1) : 446 - 446
[2] BaricitinibHerpes zoster, rebound effect in the form of flare of granuloma annulare and off-label use: case report
Reactions Weekly, 2023, 1977 (1) : 70 - 70
[3] Dexamethasone/rituximabCOVID-19 recurrence, rebound effect in the form of fever flare-up and off-label use: case report
Reactions Weekly, 2022, 1920 (1) : 191 - 191
[4] Calcitonin/denosumabVarious toxicities, rebound effect and off-label use: case report
Reactions Weekly, 2021, 1842 (1) : 105 - 105
[5] Nirmatrelvir+ritonavirViral load rebound following off-label use: case report
Reactions Weekly, 2022, 1933 (1) : 348 - 348
[6] Multiple drugsLack of efficacy following off-label use and rebound effect in the form of thrombocytopenia: 2 case reports
Reactions Weekly, 2023, 1950 (1) : 276 - 276
[7] AfliberceptRebound effect in the form of cystoid macular oedema following off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 39 - 39
[8] BevacizumabVarious toxicities and rebound effect following off-label use: 7 case reports
Reactions Weekly, 2020, 1785 (1) : 111 - 111
[9] Prednisone/triamcinolone/adalimumabLack of response and off-label use: case report
Reactions Weekly, 2022, 1901 (1) : 409 - 409
[10] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173

← 1 2 3 4 5 →